目录产品 » CLEC9A hFc Chimera, Human
Manual
SDS
COAs

CLEC9A hFc Chimera, Human

CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients.
￥3000
Z05181-100

产品简介
Species Human
Protein Construction
hFc CLEC9A (Lys57-Val241)
Accession # Q6UXN8
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized CLEC9A hFc Chimera, Human at 0.5μg/ml (100μl/Well) on the plate can bind Biotinylated Anti­CLEC9A Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 48.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients.
Synonyms CD370; CLEC9A; 9830005G06Rik; DNGR-1; HEEE9341; UNQ9341
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.